摘要
目的研究miRNA-122和miRNA-224在肝细胞癌患者和非恶性肝占位病变患者组织及血清中的表达水平的差异,以及与肝细胞癌各项临床指标的相关性。方法收集62例肝细胞癌患者和62例非恶性肝占位病变患者,采用实时荧光定量PCR与酶联免疫吸附法检测患者组织及血清中miRNA-122和miRNA-224的表达水平。结果肝细胞癌患者组织及血清中miRNA-122表达水平低于非恶性肝占位病变患者(P<0.001),且miRNA-122低表达与患者年龄、性别无关(P>0.05),但与肿瘤直径、病理分期、淋巴结转移和外周血AFP水平相关(P<0.05);miRNA-224在肝细胞癌患者组织及血清中表达水平高于非恶性肝占位病变患者(P<0.001),且miRNA-224高表达与患者年龄、性别无关(P>0.05),但与肿瘤直径、病理分期、淋巴结转移和外周血AFP水平相关(P<0.05)。结论患者血清和肝脏组织中miR-122和miR-224的表达水平对肝细胞癌的肿瘤大小、病理分期以及有无转移具有一定的判断价值,是肝细胞癌诊疗的潜在标志物。
Objective To study the differences of the expression levels of miRNA-122 and miRNA-224 in the tissues and serum of patients with hepatocellular carcinoma and patients with non-malignant hepatic space-occupying lesions,and their correlation with various clinical indicators of hepatocellular carcinoma.Methods 62 patients with hepatocellular carcinoma and 62 patients with non-malignant liver space-occupying lesions were collected.Real-time fluorescent quantitative PCR and enzyme-linked immunosorbent assay were used to detect the expression levels of miRNA-122 and miRNA-224 in the patient's tissues and serum.Results The expression level of miRNA-122 in the tissues and serum of patients with hepatocellular carcinoma was lower than that of patients with non-malignant liver space-occupying lesions(P<0.001),and the low expression of miRNA-122 was related with the patient's age and gender(P>0.05),but it was related to tumor diameter,pathological stage,lymph node metastasis and peripheral blood AFP level(P<0.05);miRNA-224 expression level in tissues and serum of patients with hepatocellular carcinoma was higher than that in patients with non-malignant liver mass lesions(P<0.001),and the high expression of miRNA-224 had nothing to do with the patient's age and gender(P>0.05),but it was related to tumor diameter,pathological stage,lymph node metastasis and peripheral blood AFP level(P<0.05).Conclusion The expression levels of miR-122 and miR-224 in the patient's serum and liver tissue have a certain value for judging the tumor size,pathological stage,and metastasis of hepatocellular carcinoma,and are potential markers for the diagnosis and treatment of hepatocellular carcinoma.
作者
王海溥
郭俊强
岳爱民
WANG Haipu;GUO Junqiang;YUE Aimin(Xinxiang Central Hospital,Xinxiang,453000)
出处
《实用癌症杂志》
2022年第3期408-411,415,共5页
The Practical Journal of Cancer
